Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Outstanding (Weighted Average) (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 5.46% to $22.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Dec 2025, up 5.46% year-over-year, with the annual reading at $22.4 million for FY2025, 5.46% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $22.4 million at Madrigal Pharmaceuticals, up from $22.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $22.4 million in Q4 2025, with the low at $15.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $19.0 million, with a median of $18.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 2.67% in 2021, then grew 13.94% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $16.5 million in 2021, then rose by 3.64% to $17.1 million in 2022, then increased by 9.05% to $18.7 million in 2023, then grew by 13.83% to $21.3 million in 2024, then grew by 5.46% to $22.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $22.4 million, $22.3 million, and $22.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.